Evidence map›Paper›PMID 42101092›Full record

Trial reportExperimental dermatology2026

A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma.

Rodrigo Pérez Pereira, Dienifer Hermann Sirena, Sérgio Jobim de Azevedo, Monique Maria Franco da Silva, Mariani Magnus da Luz Andrade, Charles Francisco Ferreira, Tiago Elias Heinen, Renato Marchiori Bakos

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rodrigo Pérez PereiraPostgraduate Program in Medical Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0002-0492-9437
Dienifer Hermann SirenaClinical Research in Oncology (UPCO), Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0002-2032-5334
Sérgio Jobim de AzevedoClinical Research in Oncology (UPCO), Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0002-9230-4284
Monique Maria Franco da SilvaPostgraduate Program in Physiology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0003-3642-9194
Mariani Magnus da Luz AndradeDepartment of Dermatology, Hospital De Clínicas De Porto Alegre, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0003-4412-9757
Charles Francisco FerreiraPostgraduate Program in Physiology, Institute of Basic Health Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0001-9777-7382
Tiago Elias HeinenClinical Research in Oncology (UPCO), Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0009-0006-4735-0288
Renato Marchiori BakosPostgraduate Program in Medical Sciences, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brazil.ORCID https://orcid.org/0000-0002-8114-246X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, new treatment strategies have been developed for advanced or metastatic basal cell carcinoma (BCC), including Hedgehog pathway inhibitors. Itraconazole has demonstrated clinical activity in such cases by blocking the smoothened (SMO) receptor. Such a strategy could be used in early disease. The objective of this Phase II study was to evaluate the clinical and molecular efficacy of Itraconazole in low-risk BCC patients who were primarily candidates for surgical excision. Lesions were assessed according to RECIST 1.1 criteria, with target lesions being at least 10 mm in size after confirmatory biopsy. Patients received itraconazole tablets 200 mg twice daily for 60 days before resection. The median tumour diameter before treatment was 14 mm (IQR 11-16 mm), and after treatment, 13 mm (IQR 11-15 mm), and this reduction in tumour size was statistically significant (p < 0.0001). Coupled with the decrease in tumour size, a decrease in the expression of CD105, an endothelial marker (p < 0.0001), was observed. In conclusion, neoadjuvant itraconazole for 2 months was able to reduce the diameter of low-risk BCC, and the effect was associated with a decrease in tumour angiogenesis and a favourable safety profile.

Indexed as

Antineoplastic AgentsBasal Cell CarcinomaItraconazoleSkin NeoplasmsAdministration, OralAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeovascularization, PathologicTreatment OutcomeAntineoplastic AgentsItraconazoleangiogenesisantineoplastic agentscancercarcinomahedgehog proteinsneoadjuvant therapyskin neoplasms

Identifiers

PMID42101092
PMCPMC13155031

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.